Key Highlights
- German pharmaceutical company Merck KGaA announces $11.3 billion acquisition of Bio-Techne
- The $73-per-share offer represents a 24% premium above Bio-Techne’s previous closing price
- Shares of Bio-Techne surged 20% to $70.58 during premarket hours on Thursday
- Transaction anticipated to finalize between late 2026 and early 2027
- Annual cost synergies projected at 140 million euros within three years post-closure
Shares of Bio-Techne (TECH) skyrocketed 20% to $70.58 during Thursday’s premarket session following the announcement that German pharmaceutical powerhouse Merck KGaA has entered into an agreement to purchase the company for $11.3 billion.
The German conglomerate is paying $73 for each share, representing a substantial 24% premium compared to where Bio-Techne closed on Wednesday. Shares of Merck KGaA also climbed 3% following the announcement.
This transaction marks the most significant acquisition Merck KGaA has undertaken in more than ten years — its last deal of similar magnitude was the 2014 acquisition of Sigma-Aldrich.
The buyout also represents the inaugural major transaction under CEO Kai Beckmann’s leadership, who assumed the role in May following Belén Garijo’s departure.
Bio-Techne is a leading provider of research reagents, proteins, antibodies, and analytical equipment utilized by scientific researchers and pharmaceutical developers. The company’s extensive portfolio features 6,000 proteins and an impressive collection of 425,000 antibodies.
During a Thursday morning media briefing, Jean-Charles Wirth, CEO of Merck’s Life Science division, described the comprehensive catalog as a “big, big plus” for their customer base.
Bolstering Life Sciences Capabilities
The strategic acquisition aims to strengthen Merck’s footprint in cutting-edge biological research and the rapidly growing cell and gene therapy sectors.
According to Merck’s statement, this transaction solidifies life sciences as the company’s principal avenue for future growth.
Puneet Souda, an analyst at Leerink, noted that Merck seems to be acquiring a compelling asset with robust long-term growth prospects, notwithstanding present challenges affecting the research tools sector.
Several market analysts have indicated they don’t anticipate significant regulatory obstacles blocking the transaction’s completion.
Financial Structure and Efficiency Gains
Merck intends to finance the acquisition through a combination of existing cash reserves and borrowed capital. According to its latest quarterly financial report, the company maintained roughly 2.74 billion euros in cash holdings.
The pharmaceutical giant projects annual cost synergies of approximately 140 million euros, which should be fully achieved three years following the deal’s completion.
The transaction is slated to reach completion sometime between late 2026 and early 2027.
This strategic move continues a broader mergers and acquisitions campaign initiated during Garijo’s tenure, which encompassed the purchases of Exelead, Mirus Bio, and SpringWorks Therapeutics, spanning mRNA production capabilities, cell and gene therapy technologies, and rare disease treatments.
According to Jean-Charles Wirth, the deal “strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences.”
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
